Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
AltruBio
AltruBio is a biopharmaceutical company developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
ProThera Biologics
ProThera Biologics develops bio-therapeutics for treating inflammatory diseases.
Sector
Subsector
Location
total rounds
total raised
Aqualung Therapeutics
Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
Sector
Subsector
Location
total rounds
total raised
viDA Therapeutics
viDA Therapeutics develops treatments for chronic inflammatory and age-related diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds6
Number of Funding Rounds
Money Raised
Their latest funding was raised on 27.04.2023. Their latest investor Alzheimer's Drug Discovery Foundation. Their latest round Series A
MRL Ventures Fund
Merck's MRL Ventures is investing in breakthrough science to develop new medicines.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Dementia Discovery Fund
Dementia Discovery Fund invests in novel science to create new medicines for dementia.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
count Of Exists
Co-Investors
Investors9
Number of lead investors
Number of investors
Alzheimer's Drug Discovery Foundation
The Alzheimer’s Drug Discovery Foundation finds drugs for Alzheimer’s disease.
Sector
Subsector
Location
count Of Investments
count Of Exists
Howard Fillit
Howard Fillit, MD, a geriatrician, neuroscientist and leading expert in Alzheimer’s disease, is the Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation. Dr. Fillit has had a distinguished academic medicine career at the Rockefeller University and the Mount Sinai School of Medicine where he is currently a clinical professor of geriatrics, medicine and neuroscience. From 1995-1998, he was the corporate medical director for Medicare at New York Life, providing program leadership for over 125,000 elderly people in several regional US markets. Throughout his career, Dr. Fillit has maintained a limited private practice in New York City in consultative geriatric medicine with a focus on Alzheimer’s disease. He has also served as a consultant to pharmaceutical and biotechnology companies, health care organizations and philanthropies. He has authored or co-authored more than 300 scientific and clinical publications, and is the senior editor of the leading international Textbook of Geriatric Medicine and Gerontology. Dr. Fillit has received several awards and honors including the Rita Hayworth Award for Lifetime Achievement.
current job
Dementia Discovery Fund
Dementia Discovery Fund invests in novel science to create new medicines for dementia.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
count Of Exists
Laurence Barker
current job
Michael Ross
Michael Ross joined SVLS as a Venture Partner in 2001, became a Managing Partner in 2002 and is based in San Francisco. Michael serves on the Thayer School of Engineering (Dartmouth College). He has also served on the boards of Carta Proteomics, Epimmune, Genencor, MetaXen, and Xenova. Michael was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha -Roche), Protropin® (hGH), Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. Michael then started Genentech's protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Michael was the Founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Novocell). Michael was also Managing Partner in Didyma, LLC, a biotechnology management consulting firm. Michael received his AB from Dartmouth College, his PhD in Chemistry at Caltech, and completed a Post Doctorate in Molecular Biology at Harvard.
current job
Sanofi Ventures
Sanofi-Genzyme BioVentures is a corporate venture capital arm of Sanofi that invests in early-stage biotech and digital health companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Jim Trenkle
Jim Trenkle is the Head of Investments at Sanofi Ventures.
People
Founders1
Katerina Akassoglou
Katerina Akassoglou is the Director, Center for Neurovascular Brain Immunology at Gladstone & UCSF at Gladstone Institutes. Katerina Akassoglou attended at Ethnikon kai Kapodistriakon Panepistimion Athinon.
current job
organization founded
Katerina Akassoglou
